Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
-
Clinical Benefit
Substantial
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial.
Clinical Added Value
moderate
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia.
Listen
